Editor’s Choice:While there’s lots of talk about PSMA scans this week, the discussion around tolerating abiraterone v. enzalutamide is my pick! (rd)
Topics Discussed
Denovo Mx diagnosis has been through most treatment options – what next?; SBRT for recurrence – Part 1 almost over; looking at trials for advanced Mx disease; abi better tolerated than enz – but what about others?; Spot RT slows doubling time – is that enough without ADT?; PSA-progression recurrence shows nothing on PSMA scan – what treatment?; man with recurrence finds an invitation-only PSMA scan; long time Mx survivor seeks PSMA scan; denovo Mx man received less than standard care and now seeks GU med onc
Chat Log
Len Sierra (to Everyone): 6:33 PM: BiTe = Bispecific T-cell Engager
Len Sierra (to Everyone): 6:35 PM: Talabostat is an experimental drug that initiates an inflammatory response in the tumor microenvironment, converting cold tumors to hot tumors and thereby making them better targets for checkpoint inhibitors, like pembro or nivolumab.
Jake Hannam (to Everyone): 6:37 PM: Why give up on enzi after just one month?
Jake Hannam (to Everyone): 6:41 PM: AR V7
Jake Hannam (to Everyone): 6:46 PM: rd@ancan.org
Mark (to Everyone): 7:04 PM: Isn’t Blue Earth for Axumin and rh-PSMA
Mark (to Everyone): 7:15 PM: Abi blocks steroid production. Won’t levels still be zero with monotherapy?
Len Sierra (to Everyone): 7:17 PM: Mark, there was a trial showing that Abi alone was just as effective in suppressing T-levels as Abi + Lupron.
Herb Geller (to Everyone): 7:27 PM: Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme By:Groenland, SL (Groenland, Stefanie L.)[ 1 ] ; van Nuland, M (van Nuland, Merel)[ 2 ] ; Bergman, AM (Bergman, Andries M.)[ 3 ] ; de Feijter, JM (de Feijter, Jeantine M.)[ 3 ] ; Dezentje, VO (Dezentje, Vincent O.)[ 3 ] ; Rosing, H (Rosing, Hilde)[ 2 ] ; Beijnen, JH (Beijnen, Jos H.)[ 2,4 ] ; Huitema, ADR (Huitema, Alwin D. R.)[ 2,5 ] ; Steeghs, N (Steeghs, Neeltje)[ 1 ] EUROPEAN JOURNAL OF CANCER Volume: 130 Pages: 32-38 DOI: 10.1016/j.ejca.2020.02.012 Published: MAY 2020
Mark (to Organizer(s) Only): 7:34 PM: The abstract did not show a lower dose, just ok for light snack.
Len Sierra (to Everyone): 7:41 PM: From Allen Edel: About 90-95% of metastatic men express at least some PSMA on their prostate cancer cells. Less aggressive PCa produces much less PSMA.
Ancan – rick : 7:42 PM: color.com
Mark (to Everyone): 8:07 PM: This is the low dose abiraterone article: J Clin Oncol . 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381.
AnCan was deeply honored to co-present the webinar “Prostate Cancer Connections: Genetics, Genomics and Prostate Cancer” with US Too International.
For the second of our three Prostate Cancer Connections webinars, we offer a discussion on genetics, genomics and prostate cancer. About this exciting emerging topic, panelist Katie Stoll states, “Genetic testing technology is changing rapidly and there are a growing number of genetic testing options available. We’re here to help you sort through the wealth of information in this new age of genetics. Our goal is to provide objective expertise and latest developments.”
Recorded on Thursday, October 15, 2020, you’ll enjoy hearing from distinguished panelists Heather H. Cheng, MD, PhD (Director, Prostate Cancer Genetics Clinic, Seattle Cancer Care Alliance), Katie Stoll, MS, LGC (Executive Director, Genetic Support Foundation), James Barrett DeLong (Patient Perspective, University of Washington School of Social Work, Lecturer Emeritus), Janet Shimabukuro (Patient Perspective).
Watch this outstanding webinar here:
For information on our peer-led video chat ACTIVE SURVEILLANCE PROSTATE CANCER VIRTUAL SUPPORT GROUP, click here.
To SIGN UP for the Group or any other of our AnCan Virtual Support groups, visit our Contact Us page.
On our third edition of The TALK, a series of webinars addressing how parents and kids of every age speak to each other about their health conditions, we had an amazing night with marvelous members of the Multiple Sclerosis community.
On Wednesday, September 30, we were honored to have Dr. Aaron Boster (Board-Certified Neurologist specializing in Multiple Sclerosis and related CNS inflammatory disorders, founder of The Boster Center for Multiple Sclerosis, and popular MS Vlogger.) gives a passionate perspective on MS and community. Brenda Miller (MS certified nurse and MS patient) moderated conversations with Dr. Boster and our excellent panelists featuring: Karrie Anderson (diagnosed in 2010), her husband, Cris, and their 13-year-old son, Kellen. Wanda Terrell (diagnosed in mid-1990s) and her 27-year-old daughter, Tazia. Justin Weiss (diagnosed in 2008), his 17-year-old daughter, Megan. And Channing Barker (diagnosed in 2006 when she was 16) with her mother, Patti.
You’ll hear about different challenges these families have experienced (and overcame), talking about your diagnosis, and how MS impacts everyone. We sincerely thank our medical experts, panelists, and co-sponsors A Couple Takes on MS; Jennifer and Dan Digmann.
Watch this amazing webinar, here:
For information on our peer-led video chat MULTIPLE SCLEROSIS VIRTUAL SUPPORT GROUP, click here.
To SIGN UP for the Group or any other of our AnCan Virtual Support groups, visit our Contact Us page.
Dr. Brian Helfand, (Head of Urology at NorthShore University HealthSystem) gave the second webinar in the four-part series called “Active Surveillance & Beyond” on September 29, 2020. His topic was genomics, genetics, and decision-making in active surveillance. He explains the pros and cons of the leading tests in the field and who may be a candidate for such testing. We want to thank Dr. Helfand for taking the time to answer several of our attendees’ questions at the end of his excellent presentation.
Also making an appearance, our AS Virtual Support Group moderators and community members, Joe Gallo, Elliot Kerman, Howard Wolinsky. Including special guests: Jim Schraidt (Chairman of Us TOO), and Beau Stubblefield-Tave (Executive Director at Us TOO).
Watch this fascinating and informative webinar here:
Our “Active Surveillance & Beyond” webinar series here at AnCan has been wildly popular. With top medical experts in AS giving incredible presentations and answering your questions, it’s a hit for a reason. We had the pleasure of having Dr. Peter Carroll (Department of Urology, UCSF), who is considered a pioneer in AS, start us off with a blast!
Hear his thoughts on biopsies, who best qualifies for AS, and how he uses AS in his own practice. We want to thank Dr. Carroll for answering so many of our attendees’ questions. You’ll also see our own AS Virtual Support Group moderators and community members, Joe Gallo, Mark Lichty, Elliot Kerman, Howard Wolinsky, and special guest: Jim Schraidt, Chairman of USTOO.
